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Gy=1.7). Irradiation with C12 induced a strong increase of 
pRb expression (2 GyE=7.7, 7 GyE=8.3). There was a minimal 
change of p53 expression after RT (2 Gy=1.3; 7 Gy=1.2, 2 
GyE=1.6, 7 GyE=1.5). S12 cells (HPV 16 integrated) showed a 
decrease of pRB expression after RT with photons (2 Gy=0.47, 
7 Gy=0.38). Irradiation with C12 enhanced the expression of 
pRb positive cells (2 GyE= 1.8,7 GyE=1.94), but showed no 
significant expression of p53 in the control group. W12 cells 
(HPV 16 episomal) showed no change of pRb expression in the 
control group or after RT. C12 RT induced an increase of pRb 
expression (2 GyE=1.5, 7 Gy=2.9). There was no significant 
change of p53 expression in W12 and S12 cells after RT. C12-
RT showed no effect on cell cycle distribution in W12/S12 
and C33A cells. 48 h after irradiation with 7 Gy photons in 
C33A cells and 24 h after RT in S12 cells a G2/M-block was 
induced. 
Conclusions: The effect of carbon-ion-RT on protein 
expression seems to be dependent on HPV-status and type of 
protein with no effect on p53 or on HPV-negative cells, but a 
strong effect on pRb expression in HPV-positive cells. The 
converse effect of carbon-ion-RT compared to photon-RT on 
HPV positive cell with integrated HPV regarding pRb 
expression indicates that carbon-ion therapy might overcome 
HPV-integration induced radioresistance. 
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Purpose/Objective: Chemoradiation followed by a 
brachytherapeutic boost is standard of care for locally 
advanced cervical cancer (LACC). In the past, we 
implemented safely the use of neo-adjuvant chemoradiation 
using arc therapy. This allowed for a safe completion 
hysterectomy. This is a report on the long-term outcome 
results of this approach.  
Materials and Methods: Fifty-nine patients with LACC were 
treated (Figo IB: n=6; II: n= 41; III: n= 9; IV: n=3) between 
12/2005 and 08/2014. Chemotherapy, administered in 51 
patients (86%), consisted of weekly cisplatin (40mg/m2). 
Radiation consisted of an Intensity Modulated Arc Therapy 
delivered in 25 fractions. No neo-adjuvant brachytherapeutic 
treatment was performed. Dose prescription was: 62 Gy and 
60 Gy (Dmed) to the primary tumour and PET/CT-positive 
lymph nodes respectively; 45 Gy (minimal dose) to the 
uterus, cervix, upper vaginal 1/3 to ½, parametria and pelvic 
lymph nodes. Para-aortic irradiation was performed if N+ 
(n=22 or 37%). 
Six weeks after the neo-adjuvant chemoradiation a 
hysterectomy was performed. Suspected lymph nodes at the 
start of the treatment were resected selectively.  
Radiotherapeutic and surgical feasibility and the low 
morbidity/toxicity rates have been published before. 
Results: Median FU is 33 months (3-101m). Median age at 
diagnosis was 56y (21-89). Pathologic complete response rate 
is 36% (ypT0: 36%; ypT1a: 26,4%; ypT1b: 28,8%, ypT2a1: 1,7%; 
ypT2b: 6,8%). Lymphnode resection was performed in 29 
patients of which 6 had positive nodes. Surgical margins were 
free of disease in all but 2 cases (a brachytherapeutic boost 
was performed). Two- and 5-year local control rates are 94%. 
Two patients relapsed in a pelvic lymph node (2- and 5-year 
regional control = 96%). Two- and 5-year distant metastasis 
free survival is 91%. One patient developed a lung metastasis 
67 months after primary diagnosis, after resection no 
progression was noted. Two- and 5-year disease-specific 
survival are both 94% and 88%. Two- and 5-year OS are 88% 
and 69% (4/9 death causes were not cervical cancer related).  
Conclusions: Neo-adjuvant chemoradiation using modern 
radiotherapy techniques leads to promising control and 
survival rates. Further research should be considered to 
confirm these promising data. 
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Purpose/Objective: Wilms tumor or nephroblastoma is the 
most common primary renal tumor of children, with about 
500 cases per year in the United States. Treatment is 
individualized by tumor histology, stage, and a variety of 
biologic factors that help determine a patients' risk strata, 
and may include surgery, chemotherapy, and radiation 
therapy. This study sought to evaluate the outcomes for 
patients with Wilms tumor treated at a single institution. 
Materials and Methods: A retrospective review was 
performed of all children with Wilms tumor treated at a 
single institution from January 1994 through December 2012. 
Patients were staged by the NWTS system and managed on- 
or per- COG protocols. Stage I and II patients were generally 
managed with surgery and adjuvant chemotherapy. Stage III 
patients were generally managed with surgery followed by 
adjuvant chemotherapy and flank/abdominal radiotherapy. 
Stage IV patients were most commonly managed with 
surgery, chemotherapy, and flank/lung radiotherapy. Stage V 
patients generally received only surgery and chemotherapy. 
MedCalc was utilized to develop Kaplan-Meier plots of 
progression free and overall survival for the population. 
Results: Of the 64 treated patients, there were 7 patients 
with recurrence (10.9%). There were no recurrences in 11 
patients with stage I disease.  
There were 15 patients with stage II disease of which 3 
patients (20%) experienced recurrence. Two patients 
